BioSpace News Archive

Ocuphire Pharma, Inc. announced that data from its Phase 2 clinical trial of APX3330 in Diabetic Retinopathy were featured in an oral presentation on Saturday, August 26th at the Women in Ophthalmology Summer Symposium, in Marco Island, Florida.

Harmony Biosciences Holdings, Inc. (“Harmony” or the “Company”) (Nasdaq: HRMY) today commented on the favorable decision by the U.S. Patent and Trademark Office (USPTO) to deny a Petition for Reexamination concerning a patent covering the active ingredient in WAKIX® (pitolisant).

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from the APHENITY clinical trial and long-term extension study will be presented at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2023 which is being held from Aug. 29 to Sept. 1 in Jerusalem, Israel.

Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, announced that global biopharmaceutical company and cell therapy developer Bristol Myers Squibb (NYSE: BMY) has joined its Technology Adoption Partnership (TAP) program.

Tris Pharma, Inc. announced that the company has been awarded a grant expected to provide up to $16.6M over five years from the National Institute on Drug Abuse, part of the National Institutes of Health.

NanoString Technologies, Inc., a provider of life science tools for discovery and translational research, announced that Todd Garland has been appointed Chief Commercial Officer, effective August 28, 2023.

Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, has been named to Fierce Biotech’s 2023 “Fierce 15” list, designating it as one of the most outstanding early-stage biotechnology companies in the industry.

KalVista Pharmaceuticals, Inc. announced the acceptance of multiple abstracts at the 2023 HAEi Regional Conference EMEA meeting taking place in Munich, Germany from September 1-3.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) today announced that it will be presenting analyses highlighting patient-focused endpoints from its Essential1 study of ulixacaltamide (PRAX-944) in essential tremor (ET) at The International Parkinson and Movement Disorder Society’s (MDS) International Congress of Parkinson’s Disease and Movement Disorders®, taking place in Copenhagen, Denmark.

Genelux Corporation, a late clinical-stage immuno-oncology company, announced that Lourie S. Zak will join the company as Chief Financial Officer, effective August 28, 2023.